Claims Scope:

Patent issued October 21, 2022. 

 

A composition of transduced PMBCs  

(a) obtaining PBMC from a patient infected with HIV, previously immunized with a first stimulatory agent to enrich a population of HIV-specific CD4+ T cells;  

(b) contacting the PBMC with a second stimulatory agent ex vivo;  

(c) positively selecting HIV-specific CD4+ T cells ex vivo from the PBMC; and  

(d) transducing the PBMC ex vivo with a viral delivery system encoding a sequence having  

(i) at least 90% sequence identity with SEQ ID NO: 31 (Vif, Tat, and CCR5, guide + RNA backbone; in ordered sequence); or 

(ii) at least 90% sequence identity with SEQ ID NO: 1 (mir30 CCR5 guide + backbone), and at least 90% sequence identity with SEQ ID NO: 2 (mir21 Vif guide + backbone), and at least 90% sequence identity with SEQ ID NO: 111 (mir185 Tat guide + backbone; in any order); or 

(iii) at least 90% sequence identity with SEQ ID NO: 97 (CCR5 guide sequence) incorporated into a microRNA backbone (unspecified), at least 90% sequence identity with SEQ ID NO: 6 (Vif guide sequence) incorporated into a microRNA backbone (unspecified), and at least 90% sequence identity with SEQ ID NO: 7 (Tat guide sequence) incorporated into any microRNA backbone (in any order),  

(e) culturing the PBMC for at least one day.